Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
TWINS
2 other identifiers
interventional
200
1 country
22
Brief Summary
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. It is the most common cause of neurological disability in young adults, involving a long-term therapeutic follow-up. 85% of the patients are diagnosed with Relapsing-Remitting form of MS (RRMS). This form is characterized by clearly defined acute or subacute neurological symptoms (relapses) followed by periods of partial to complete recovery. Disease-modifying therapies (DMT) used to treat RRMS are immunomodulatory or suppressor molecules which have proven efficacy in limiting disease activity (decreasing relapse rate and delaying time to disease progression). However, the long-term safety of DMT is uncertain, as there is an increased risk of developing adverse events or infections (sometimes severe) such as observed in the last pandemic of COVID-19 (higher risk of infection), highlighting the need to reassess the benefit/risk ratio of maintaining immunomodulatory or suppressive therapy in the MS population. In elderly patients with comorbidity, this risk is further increased. To date, few studies on the discontinuation of treatment in elderly RRMS patients have been conducted. However, those available demonstrate that there was no difference in relapse rates between patients who continued or discontinued treatment. These results are consistent with immunosenescence studies in RRMS that suggested a negative correlation between relapse rate/inflammatory processes and age. On the contrary, there is evidence indicating a positive correlation between age and the number of infections. In addition, in the current context in France, it is important to take into account the medico-social cost associated with long-term treatments. In France, the average estimated annual cost per patient is 12,000€, more than half of which is attributed to medications.Furthermore, with age progression, an inversion of the benefit/cost assessment has been observed in treated patients. Considering these medical and medico-social factors, it is reasonable to question the value of continuing treatment in stable patients with RRMS over 55 years. This is a randomized, controlled, multicentric, open-label, parallel groups, 1:1 ratio non-inferiority clinical trial, comparing (1) a group that will stop treatment, to (2) a group that will continue treatment, over the course of 2 years, to determine the survival rate without MS activity defined clinically or by imaging. The patients in both arms will be followed over 2 years after randomization. 5 visits will be performed for all patients: inclusion/randomization visit (M0) and 4 follow-up visits every 6 months (M6, M12, M18, and M24). An additional phone call at M3 is planned.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jan 2025
Typical duration for phase_3
22 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 22, 2024
CompletedFirst Posted
Study publicly available on registry
October 29, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2029
January 3, 2025
January 1, 2025
2 years
October 22, 2024
January 2, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Time to first clinical and/or radiological disease activity during a period of 2 years.
A clinical activity (relapse) is defined by the occurrence of new or worsening of neurological symptoms linked to MS. Relapses must meet the following criteria: * Symptoms must last at least 24 hours, without other clinical factors leading to confusion (fever, infection, lesion, drug adverse events) * Must be followed by improvement or resolution of the neurological state within 30 days * New symptoms or worsening of neurological state must be accompanied by an objective neurologic state aggravation * The neurological symptom must be linked to the modified FSS (pyramidal, cerebellar, brainstem, sphincter, mental, sensory or visual functions) A radiological activity is defined if MRI shows either: * at least 3 new or enlarged T2 ≥ 3 mm on the same exam or * at least 3 cumulative new or enlarged T2 lesions ≥ 3 mm during follow up or * one enhanced gadolinium lesion compared to the previous MRI.
From enrollment to the end of study visit at 24 months
Study Arms (2)
Experimental
EXPERIMENTALTreatment withdrawal; patients will stop their Disease Modifying Treatment (DMT)
Control arm
ACTIVE COMPARATORPatients will continue their DMT as per routine pratice
Interventions
Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
Eligibility Criteria
You may qualify if:
- Patient (male or female) aged 55 and over
- RRMS diagnosis according to revised McDonald 2017 criteria
- First MS symptom \>5 years ago. If the date is unknown, RRMS diagnosis \>5 years ago
- Stable disease in the last 5 years according to the revised Lublin and Reingold classification characterized by :
- Treated with a Moderate Efficacy Therapy (MET) for at least 5 consecutive years (IFN-β, glatiramer acetate, dimethyl fumarate, teriflunomide, diroximel fumarate); switching from one first-line treatment to another is accepted if the reason for the change is related to personal convenience or intolerance to the first treatment.
- Patient with affiliation to a social security regimen
- Patient able to understand the objectives and risks associated with the research and to give informed consent to the study
- Patient willing and able to comply with study procedures for the duration of the study
You may not qualify if:
- Primary progressive or secondary progressive with or without relapse as defined by the revised Lublin and Reingold classification
- Contraindication to MRI (claustrophobia, weight ≥ 140 kg, pacemaker, cochlear implants, foreign body in eye, intracranial vascular clips, surgery in the 6 weeks prior to the beginning of the study, coronary stent implanted in the 8 weeks prior to the beginning of the study,…).
- NB : Gadolinium contraindication will not prevent recruitment of the patient; in this case MRI will be carried out without contrast product injection
- History of neurological disease affecting the central nervous system: hereditary degenerative CNS disease, degenerative cognitive disease, systemic autoimmune disease, sarcoidosis, Lyme disease…
- Chronic disease which requires chronic treatment with corticoids or immunosuppressors
- Uncontrolled cardiac, renal or hepatic disease
- Patient wishing to discontinue background therapy, whether or not they are experiencing adverse effects.
- Patient not considering discontinuing background therapy, whether or not they are experiencing adverse effects.
- Pregnant or breastfeeding woman
- Patient with difficulty to read or understand French,
- Patient subject to a legal protection measure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (22)
CHU de Bordeaux-Hôpital Pellegrin
Bordeaux, 33076, France
CHU de Caen-Hôpital Côte de Nacre
Caen, 14033, France
CHU de Clermont-Ferrand-Hôpital Gabriel Montpied
Clermont-Ferrand, 63003, France
Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Henri Mondor
Créteil, 94010, France
CHU de Dijon-Hôpital du Bocage
Dijon, 21079, France
CH de Gonesse
Gonesse, 95500, France
CHU de Grenoble Alpes
La Tronche, 38700, France
Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital Saint Vincent de Paul
Lille, 59020, France
CHU de Lille-Hôpital Roger Salengro
Lille, 59037, France
CHU de Limoges-Hôpital Dupuytren
Limoges, 87042, France
Assistance Publique des Hôpitaux de Marseille (APHM)-Hôpital La Timone Adultes
Marseille, 13005, France
CHU de Montpellier-Hôpital G. De Chauliac
Montpellier, 34295, France
CHU de Nancy -Hôpital Central
Nancy, 54035, France
CHU de Nice-Hôpital Pasteur
Nice, 06002, France
CHU de Nîmes
Nîmes, 30029, France
Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Pitié-Salpêtrière
Paris, 75013, France
Fondation Ophtalmologique Rothschild
Paris, 75019, France
CHU de Rennes-C.H.R. Pontchaillou
Rennes, 35033, France
CHU de Rouen-Hôpital Charles Nicolle
Rouen, 76038, France
CHU Nantes -CIC de Neurologie
Saint-Herblain, 44 093, France
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, 67000, France
CHU de Tours
Tours, 37044, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicolas COLLONGUES, MD, PhD
University Hospital, Strasbourg, France
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2024
First Posted
October 29, 2024
Study Start
January 1, 2025
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
June 1, 2029
Last Updated
January 3, 2025
Record last verified: 2025-01